{"id":"gbs-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Pain, redness, or swelling at the injection site"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The vaccine contains inactivated Group B strep bacteria, which are used to trigger an immune response. This immune response helps the body to recognize and fight off future infections caused by Group B strep.","oneSentence":"GBS Vaccine works by stimulating the body's immune system to produce antibodies against the bacteria that cause Group B strep infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:37:23.282Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of Group B strep infection in pregnant women and newborns"}]},"trialDetails":[{"nctId":"NCT06833957","phase":"","title":"Preparing for Maternal GBS Vaccine Trials in Africa","status":"RECRUITING","sponsor":"Barcelona Institute for Global Health","startDate":"2025-03-01","conditions":"Group B Streptococcus, Invasive Bacterial Diseases (IBD), Maternal Immunization","enrollment":18100},{"nctId":"NCT06280157","phase":"","title":"A Follow up Study of Group B Streptococcus (GBS)-NN/NN2 Vaccine in Healthy Volunteers","status":"TERMINATED","sponsor":"Minervax ApS","startDate":"2024-01-18","conditions":"Group B Streptococcus Infection","enrollment":29},{"nctId":"NCT06592586","phase":"PHASE2, PHASE3","title":"A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women","status":"RECRUITING","sponsor":"Minervax ApS","startDate":"2025-03-07","conditions":"Streptococcus Agalactiae Infection, Neonatal Sepsis, Pneumonia","enrollment":338},{"nctId":"NCT06611371","phase":"PHASE1, PHASE2","title":"Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inventprise Inc.","startDate":"2024-11-12","conditions":"Group B Streptococcal Infections","enrollment":600},{"nctId":"NCT05782179","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants","status":"COMPLETED","sponsor":"Minervax ApS","startDate":"2023-03-01","conditions":"Group B Streptococcal Infections","enrollment":90},{"nctId":"NCT05154578","phase":"PHASE2","title":"Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women","status":"COMPLETED","sponsor":"Minervax ApS","startDate":"2022-02-17","conditions":"Group B Streptococcal Infection","enrollment":269},{"nctId":"NCT05212792","phase":"","title":"Genomics and COVID-19 Vaccine Adverse Events","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2022-06-24","conditions":"Vaccine Adverse Reaction","enrollment":6325},{"nctId":"NCT05005247","phase":"PHASE1","title":"Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine","status":"COMPLETED","sponsor":"Minervax ApS","startDate":"2021-08-17","conditions":"Group B Streptococcus Infection","enrollment":27},{"nctId":"NCT06494475","phase":"PHASE2, PHASE3","title":"GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age","status":"NOT_YET_RECRUITING","sponsor":"Minervax ApS","startDate":"2024-12-17","conditions":"Streptococcus Agalactiae Infection","enrollment":564},{"nctId":"NCT02690181","phase":"PHASE2","title":"Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-03-29","conditions":"Bacterial Infection Due to Streptococcus, Group B, Streptococcus Agalactiae","enrollment":80},{"nctId":"NCT04653948","phase":"","title":"Maternal, Neonatal and Infant Outcomes at Kawempe National Referral Hospital","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2019-10-01","conditions":"Group B Streptococcus Carrier in Childbirth, Group B Streptococcal Infection, Late-Onset, Group B Streptococcal Infection, Early-Onset","enrollment":3423},{"nctId":"NCT04735419","phase":"","title":"Development of a Serocorrelate of Protection Against Invasive Group B Streptococcus Disease","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2021-12-01","conditions":"Streptococcus Agalactiae Infection","enrollment":400},{"nctId":"NCT04596878","phase":"PHASE2","title":"Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV","status":"COMPLETED","sponsor":"Minervax ApS","startDate":"2020-11-19","conditions":"Group B Streptococcal Infection","enrollment":205},{"nctId":"NCT03807245","phase":"PHASE1","title":"Group B Streptococcus Vaccine in Healthy Females","status":"COMPLETED","sponsor":"Minervax ApS","startDate":"2019-01-09","conditions":"Group B Strep Infection","enrollment":60},{"nctId":"NCT02459262","phase":"PHASE1","title":"Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age.","status":"COMPLETED","sponsor":"Minervax ApS","startDate":"2015-05","conditions":"Infection by Streptococcus Group B","enrollment":240},{"nctId":"NCT02046148","phase":"PHASE2","title":"Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-18","conditions":"GBS Disease, Streptococcus Agalactiae","enrollment":75},{"nctId":"NCT01053767","phase":"PHASE1","title":"A Study to Assess the Persistence of Two GBS Antibodies in Women Previously Immunized With a GBS Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-01","conditions":"Group B Streptococcus (GBS) Disease","enrollment":95},{"nctId":"NCT02270944","phase":"PHASE2","title":"Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11-20","conditions":"Infections, Streptococcal, Streptococcal Infections","enrollment":1053},{"nctId":"NCT01052935","phase":"PHASE1","title":"A Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS Vaccine","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-01","conditions":"Group B Streptococcus (GBS) Disease","enrollment":50},{"nctId":"NCT01150123","phase":"PHASE1","title":"Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-05","conditions":"Group B Streptococcus","enrollment":678},{"nctId":"NCT00575653","phase":"","title":"Safety Study of GBS Following Menactra Meningococcal Vaccination","status":"COMPLETED","sponsor":"Harvard Pilgrim Health Care","startDate":"2005-03","conditions":"Guillain-Barre Syndrome","enrollment":6000000},{"nctId":"NCT00128219","phase":"PHASE2","title":"Prevention of GBS Colonization Via Immunity","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-07","conditions":"Beta Haemolytic Streptococcal Infection","enrollment":667},{"nctId":"NCT01412801","phase":"PHASE2","title":"Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-09","conditions":"Streptococcal Infections, Gram-Positive Bacterial Infections, Bacterial Infections","enrollment":270},{"nctId":"NCT01446289","phase":"PHASE2","title":"Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-09","conditions":"Streptococcal Infection, Gram-positive Bacterial Infection, Bacterial Infection","enrollment":86},{"nctId":"NCT01193920","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-10","conditions":"Streptococcal Infections","enrollment":380},{"nctId":"NCT00657683","phase":"PHASE1","title":"A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Monovalent Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-12","conditions":"Invasive Group B Streptococcus (GBS) Disease","enrollment":65},{"nctId":"NCT00645346","phase":"PHASE1","title":"A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18- 40 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-02","conditions":"Invasive Group B Streptococcus (GBS) Disease","enrollment":130},{"nctId":"NCT00008853","phase":"PHASE1","title":"Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Bacterial Infections, Group B Streptococcus","enrollment":65}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":186,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GBS Vaccine","genericName":"GBS Vaccine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"The GBS Vaccine is a vaccine component that induces an immune response, used to prevent Group B Streptococcus Infections, which can occur in newborns and pregnant women. It is administered in a Phase I clinical trial to evaluate its safety, tolerability, and immunogenicity in healthy females.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}